Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

Cancer Research

Volumn 61, Issue 17, 2001, Pages 6500-6510

  Albanell, Joan ^a   Codony Servat, Jordi ^a   Rojo, Federico ^a   Del Campo, José M ^a   Sauleda, Silvia ^a   Anido, Judit ^a   Raspall, Guillermo ^a,b   Giralt, Jordi ^a,b   Roselló, José ^a   Nicholson, Robert I ^c   Mendelsohn, John ^d   Baselga, José ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; AUTOCRINE EFFECT; CANCER RECURRENCE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035418622     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Receptors for epidermal growth factor and other polypeptide mitogens
2. Biochemical and clinical implications of ErbB/HER signaling network of growth factor receptors
3. Autocrine interaction between TGF-α and the EGF-receptor: Quantitative requirements for induction of the malignant phenotype
4. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival
5. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
6. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
7. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
8. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter
9. Continuous administration of ZD1839 (Iressa), a novel epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
10. Continued response following treatment with IMC-C225, an EGFR MoAb, combined with RT in advanced head and neck malignancies
11. Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFR), for patients with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens
12. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
13. Signal transduction through MAP kinase cascades
14. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis
15. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis
16. Constitutive activation of mitogenactivated protein (MAP) kinases in human renal cell carcinoma
17. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma
18. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
19. Activation of mitogen-activated protein kinase associated with prostate cancer progression
20. In situ visualization of intratumor growth factor signaling: Immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms
21. Biological and clinical associations of c-jun activation in human breast cancer
22. A family of proteins that inhibit signaling through tyrosine kinase receptors
23. Strain-dependent epithelial defects in mice lacking the EGF receptor
24. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype
25. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
26. The EGF receptor-an essential regulator of multiple epidermal functions
27. Immunolocalization of epidermal growth factor receptors in normal developing human skin
28. HER2 and choice of adjuvant chemotherapy for invasive breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-15
29. Epidermal growth factor-related peptides and their receptors in human malignancies
30. Her-2/neu oncogene characterization in head and neck squamous cell carcinoma
31. High telomerase activity in primary lung cancers: Association with increased cell proliferation rates and advanced pathologic stage
32. Overexpression of the ERK/MAP kinases in oral squamous cell carcinoma
33. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation
34. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
35. Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation
36. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-α bigenic mice
37. Pharmacodynamic effects of Iressa, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in skin biopsies from cancer patients participating in a Phase I trial